Literature DB >> 7988780

Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM.

J Jeppesen1, M Y Zhou, Y D Chen, G M Reaven.   

Abstract

The primary goal of the present study was to examine the effects of improved glycaemic control associated with glipizide treatment on postprandial lipaemia in non-insulin-dependent diabetic patients. The metabolism of triglyceride-rich lipoproteins of intestinal origin was assessed by measuring the retinyl palmitate content in plasma and the Svedberg flotation index (Sf) > 400 and Sf 20-400 lipoprotein fractions. Fasting plasma glucose concentrations (14.5 +/- 0.5 vs 9.0 +/- 0.5 mmol/l), glycated haemoglobin levels (13.1 +/- 0.6 vs. 9.7 +/- 0.6%), and daylong plasma glucose concentrations were all significantly lower after glipizide treatment (p < 0.001). The improvement in glycaemic control was associated with increases in insulin-mediated glucose uptake (p < 0.001) and plasma post-heparin lipoprotein and hepatic lipolytic activities (p < 0.02). Both fasting plasma triglyceride (3.09 +/- 0.51 vs 2.37 +/- 0.34 mmol/l), and postprandial triglyceride concentrations (p < 0.05-0.001) were lower following glipizide treatment, associated with a significant fall in retinyl palmitate content in all three lipoprotein fractions (p < 0.02-0.001), with the most substantial decrease seen in the Sf20-400 fraction. These data indicate that glipizide-induced improvement in glycaemic control was associated with changes in the metabolism of triglyceride-rich lipoproteins of intestinal origin that would be anticipated to reduce risk of coronary heart disease in non-insulin-dependent diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988780     DOI: 10.1007/BF00404335

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  34 in total

1.  Postprandial lipemia, fenofibrate and coronary artery disease.

Authors:  H S Simpson; C M Williamson; T Olivecrona; S Pringle; J Maclean; A R Lorimer; F Bonnefous; Y Bogaievsky; C J Packard; J Shepherd
Journal:  Atherosclerosis       Date:  1990-12       Impact factor: 5.162

2.  Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin.

Authors:  I Juhan-Vague; C Roul; M C Alessi; J P Ardissone; M Heim; P Vague
Journal:  Thromb Haemost       Date:  1989-06-30       Impact factor: 5.249

3.  Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy.

Authors:  M R Taskinen; W F Beltz; I Harper; R M Fields; G Schonfeld; S M Grundy; B V Howard
Journal:  Diabetes       Date:  1986-11       Impact factor: 9.461

4.  Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.

Authors:  J R Patsch; G Miesenböck; T Hopferwieser; V Mühlberger; E Knapp; J K Dunn; A M Gotto; W Patsch
Journal:  Arterioscler Thromb       Date:  1992-11

5.  Lipid metabolism in non-insulin-dependent diabetes mellitus: effect of glipizide therapy.

Authors:  M S Greenfield; L Doberne; M Rosenthal; H J Vreman; G M Reaven
Journal:  Arch Intern Med       Date:  1982-08

6.  Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study.

Authors:  L A Simons; T Dwyer; J Simons; L Bernstein; P Mock; N S Poonia; S Balasubramaniam; D Baron; J Branson; J Morgan
Journal:  Atherosclerosis       Date:  1987-05       Impact factor: 5.162

7.  Delayed clearance of chylomicron remnants following vitamin-A-containing oral fat loads in broad-beta disease (type III hyperlipoproteinemia).

Authors:  W R Hazzard; E L Bierman
Journal:  Metabolism       Date:  1976-07       Impact factor: 8.694

8.  Changes in carbohydrate metabolism in association with glipizide treatment of type 2 diabetes.

Authors:  C Y Jeng; C B Hollenbeck; M S Wu; J E Foley; Y D Chen; G M Reaven
Journal:  Diabet Med       Date:  1991-01       Impact factor: 4.359

9.  HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age.

Authors:  F Karpe; J M Bard; G Steiner; L A Carlson; J C Fruchart; A Hamsten
Journal:  Arterioscler Thromb       Date:  1993-01

10.  Comparison of cholesteryl ester transfer from chylomicrons and other plasma lipoproteins to aortic intima media of cholesterol-fed rabbits.

Authors:  S Stender; D B Zilversmit
Journal:  Arteriosclerosis       Date:  1982 Nov-Dec
View more
  4 in total

1.  Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Authors:  N Matikainen; S Mänttäri; A Schweizer; A Ulvestad; D Mills; B E Dunning; J E Foley; M-R Taskinen
Journal:  Diabetologia       Date:  2006-07-01       Impact factor: 10.122

Review 2.  Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.

Authors:  Barbara E Stähli; Catherine Gebhard; Jean-Claude Tardif
Journal:  Curr Cardiol Rep       Date:  2015-07       Impact factor: 2.931

Review 3.  Intestinal lipid absorption and transport in type 2 diabetes.

Authors:  Bruno Vergès
Journal:  Diabetologia       Date:  2022-07-30       Impact factor: 10.460

4.  Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus.

Authors:  Erina Shigematsu; Tadashi Yamakawa; Kazuaki Kadonosono; Yasuo Terauchi
Journal:  J Clin Med Res       Date:  2014-07-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.